- Home
- OCCI vs CGEN Comparison
OCCI vs CGEN Comparison
Compare OCCI & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OCCI
- CGEN
- Stock Information
- Founded
- OCCI N/A
- CGEN 1993
- Country
- OCCI United States
- CGEN Israel
- Employees
- OCCI N/A
- CGEN N/A
- Industry
- OCCI Trusts Except Educational Religious and Charitable
- CGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- OCCI Finance
- CGEN Health Care
- Exchange
- OCCI Nasdaq
- CGEN Nasdaq
- Market Cap
- OCCI 152.2M
- CGEN 125.3M
- IPO Year
- OCCI N/A
- CGEN 2000
- Fundamental
- Price
- OCCI $5.54
- CGEN $1.63
- Analyst Decision
- OCCI
- CGEN
- Analyst Count
- OCCI 0
- CGEN 0
- Target Price
- OCCI N/A
- CGEN N/A
- AVG Volume (30 Days)
- OCCI 115.8K
- CGEN 369.6K
- Earning Date
- OCCI 12-11-2023
- CGEN 11-11-2025
- Dividend Yield
- OCCI 24.32%
- CGEN N/A
- EPS Growth
- OCCI N/A
- CGEN N/A
- EPS
- OCCI N/A
- CGEN N/A
- Revenue
- OCCI N/A
- CGEN $22,144,000.00
- Revenue This Year
- OCCI N/A
- CGEN N/A
- Revenue Next Year
- OCCI $10.19
- CGEN $208.08
- P/E Ratio
- OCCI N/A
- CGEN N/A
- Revenue Growth
- OCCI N/A
- CGEN N/A
- 52 Week Low
- OCCI $5.47
- CGEN $1.13
- 52 Week High
- OCCI $10.15
- CGEN $2.66
- Technical
- Relative Strength Index (RSI)
- OCCI 43.06
- CGEN 62.55
- Support Level
- OCCI $5.36
- CGEN $1.30
- Resistance Level
- OCCI $5.54
- CGEN $1.47
- Average True Range (ATR)
- OCCI 0.15
- CGEN 0.10
- MACD
- OCCI -0.01
- CGEN 0.04
- Stochastic Oscillator
- OCCI 40.24
- CGEN 63.46
About OCCI OFS Credit Company Inc.
OFS Credit Co Inc is a non-diversified, closed-end management investment company. Its investment objective is to generate current income, with a secondary objective to generate capital appreciation through investment in collateralized loan obligation (CLO) equity and debt securities. The company invests in floating rate credit instruments and other structured credit investments, including; collateralized loan obligation (CLO) debt and subordinated (i.e., residual or equity) securities; traditional corporate credit investments, including leveraged loans and high yield bonds; opportunistic credit investments, including stressed and distressed credit situations and long/short credit investments; and other credit-related instruments.
About CGEN Compugen Ltd.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.